Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) saw a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 4,608,596 shares, a growth of 30.4% from the September 15th total of 3,533,483 shares. Based on an average daily trading volume, of 1,244,521 shares, the short-interest ratio is currently 3.7 days. Approximately 9.2% of the company’s stock are short sold.

A number of equities research analysts have issued reports on the stock. Chardan Capital reissued a “buy” rating and set a $10.00 target price on shares of Aralez Pharmaceuticals in a research note on Sunday, August 14th. Guggenheim reissued a “buy” rating and set a $12.00 target price on shares of Aralez Pharmaceuticals in a research note on Monday, August 15th.

Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 4.80 on Friday. The firm’s market cap is $313.16 million. The company has a 50 day moving average of $5.26 and a 200 day moving average of $4.22. Aralez Pharmaceuticals has a 1-year low of $3.10 and a 1-year high of $8.59.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The business earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. The business’s quarterly revenue was up 142.3% compared to the same quarter last year. On average, equities analysts forecast that Aralez Pharmaceuticals will post ($1.06) earnings per share for the current fiscal year.

In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of Aralez Pharmaceuticals stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the sale, the director now owns 669,094 shares of the company’s stock, valued at approximately $3,894,127.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.77% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. California Public Employees Retirement System increased its stake in shares of Aralez Pharmaceuticals by 10.0% in the second quarter. California Public Employees Retirement System now owns 105,867 shares of the company’s stock valued at $349,000 after buying an additional 9,667 shares during the last quarter. Alps Advisors Inc. increased its stake in shares of Aralez Pharmaceuticals by 24.9% in the second quarter. Alps Advisors Inc. now owns 89,850 shares of the company’s stock valued at $297,000 after buying an additional 17,920 shares during the last quarter. Janus Capital Management LLC increased its stake in shares of Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock valued at $5,292,000 after buying an additional 20,623 shares during the last quarter. FNY Managed Accounts LLC increased its stake in shares of Aralez Pharmaceuticals by 73.3% in the second quarter. FNY Managed Accounts LLC now owns 52,000 shares of the company’s stock valued at $172,000 after buying an additional 22,000 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Aralez Pharmaceuticals during the second quarter valued at approximately $100,000. Institutional investors and hedge funds own 49.63% of the company’s stock.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Stock Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.